Ranbaxy Laboratories today said it had made further three filings of its anti-retroviral (ARSs) formulations to the World Health Organisation for approval under its pre-qualification project for HIV/aids drugs.With this, the total number of filings submitted by the company to the WHO increases to 11, of which, five are fixed dose combinations, ranbaxy informed the BSE.All the ARVs filed by the company to who are manufactured at a plant inspected and approved by the USFDA, it added.Commenting on the progress of the company's ARV filings, Ranbaxy CEO and MD Brian W Tempest said, "With these recent filings, we have already resubmitted the majority of our dossiers with WHO. We are working with speed and focus to submit almost all our ARVs with WHO and USFDA this year."
